Beam Therapeutics Inc BEAM:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 7:51 PM EDT29.20
-0.35 (-1.18%)
-0.35 (-1.18%)Volume
43,066
Close
29.55
+0.59 (+2.04%)
+0.59 (+2.04%)Volume
1,107,230
52 week range
15.60 - 36.44
- Open28.71
- Day High29.65
- Day Low28.30
- Prev Close28.96
- 52 Week High36.44
- 52 Week High Date01/12/26
- 52 Week Low15.60
- 52 Week Low Date08/21/25
Latest On Beam Therapeutics Inc
Key Stats
- Market Cap3.04B
- Shares Out102.88M
- 10 Day Average Volume1.81M
- Dividend-
- Dividend Yield-
- Beta2.20
Latest On Beam Therapeutics Inc
KEY STATS
- Open28.71
- Day High29.65
- Day Low28.30
- Prev Close28.96
- 52 Week High36.44
- 52 Week High Date01/12/26
- 52 Week Low15.60
- 52 Week Low Date08/21/25
- Market Cap3.04B
- Shares Out102.88M
- 10 Day Average Volume1.81M
- Dividend-
- Dividend Yield-
- Beta2.20
RATIOS/PROFITABILITY
- EPS (TTM)-0.64
- P/E (TTM)-46.05
- Fwd P/E (NTM)-6.45
- EBITDA (TTM)-349.251M
- ROE (TTM)-5.69%
- Revenue (TTM)164.011M
- Gross Margin (TTM)-
- Net Margin (TTM)-39.66%
- Debt To Equity (MRQ)8.60%
EVENTS
- Earnings Date08/03/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREBeam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it...
John Evans
Chief Executive Officer, Director
Giuseppe Ciaramella Ph.D.
President
Sravan Emany
Chief Financial Officer
Address
238 Main Street
Cambridge, MA
02142
United States